Login  /  Register  | 3 premium articles left before you must register.

Pfizer arthritis drug gaining ground

Published July 27. 2013 4:00AM

The user base for a Pfizer Inc. therapy aimed at rheumatoid arthritis patients has more than doubled in the past three months.

The drug, Xeljanz, was developed at Pfizer's campus in Groton and received regulatory approval about six months ago.

BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceuticals, said in a news release that 61 percent of rheumatologists surveyed are now trying Xeljanz in their patient populations. This compares with a trial rate of 32 percent three months ago.

Specialists averaged only six patients on Xeljanz, though they anticipated numbers would increase in the future.

News by Town

Most Recent Poll
Goodbye, July. How will you spend the last month of school vacation?
I've saved all year to take my family on an out-of-state vacation.
I'll enjoy all the outdoor concerts, seafood dinners and beach outings southeast Connecticut has to offer.
I'll start compiling my back-to-school shopping list.
I'm feeling life is short so I'm seizing the moment. I'm reeling from the news Mick Jagger turned 70.
Number of votes: 546

No current items found